Inflammatory immune-mediated adverse reactions induced by COVID-19 vaccines in previously injected patients with soft tissue fillers

Autor: Jaume Alijotas‐Reig, Victor García‐GImenez, Peter J. Velthuis, Frank B. Niessen, Tom S. Decates
Přispěvatelé: Institut Català de la Salut, [Alijotas-Reig J] Unitat de Malalties Autoimmunes Sistèmiques, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [García-GImenez V] Europe Medical Centre, Barcelona, Spain. Sociedad Española de Medicina y Cirugía Cosmética, Barcelona, Spain. [Velthuis PJ, Decates TS] Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands. [Niessen FB] Department of Plastic Surgery, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands, Vall d'Hebron Barcelona Hospital Campus, Dermatology, Plastic, Reconstructive and Hand Surgery, AII - Inflammatory diseases, AMS - Tissue Function & Regeneration
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Inflammation
acciones y usos químicos::usos especializados de productos químicos::materiales biomédicos y dentales::rellenos dérmicos [COMPUESTOS QUÍMICOS Y DROGAS]
Vaccines
COVID-19 Vaccines
Complex Mixtures::Biological Products::Vaccines [CHEMICALS AND DRUGS]
SARS-CoV-2
Medicaments - Efectes secundaris
COVID-19
Soft tissue fillers
Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]
Dermatology
Pathological Conditions
Signs and Symptoms::Pathologic Processes::Inflammation [DISEASES]
Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores]
Inflamació
Injections
SDG 3 - Good Health and Well-being
Dermal Fillers
Other subheadings::Other subheadings::/adverse effects [Other subheadings]
afecciones patológicas
signos y síntomas::procesos patológicos::inflamación [ENFERMEDADES]
virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]
Humans
Adverse reactions
Chemical Actions and Uses::Specialty Uses of Chemicals::Biomedical and Dental Materials::Dermal Fillers [CHEMICALS AND DRUGS]
COVID-19 (Malaltia) - Vacunació
mezclas complejas::productos biológicos::vacunas [COMPUESTOS QUÍMICOS Y DROGAS]
Zdroj: Scientia
Journal of Cosmetic Dermatology, 21(8), 3181-3187. Wiley-Blackwell Publishing Ltd
Alijotas-Reig, J, García-GImenez, V, Velthuis, P J, Niessen, F B & Decates, T S 2022, ' Inflammatory immune-mediated adverse reactions induced by COVID-19 vaccines in previously injected patients with soft tissue fillers : A case series of 20 patients ', Journal of Cosmetic Dermatology, vol. 21, no. 8, pp. 3181-3187 . https://doi.org/10.1111/jocd.15117
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
ISSN: 1473-2165
1473-2130
Popis: COVID-19; Inflammation; Soft tissue fillers COVID-19; Inflamación; Rellenos de tejidos blandos COVID-19; Inflamació; Farciments de teixits tous Background Adverse events (AE) after COVID-19 vaccines, particularly, but not solely, with those messenger RNA (mRNA)-based vaccines, have rarely been reported in patients previously treated with dermal fillers (DF). Objective To evaluate the morphology, clinical characteristics, the timing of presentation, and outcomes of inflammatory AE appeared in patients injected with DF, after anti-COVID-19 vaccination. Methods Descriptive study of a case series of 20 consecutive patients collected after the occurrence of AE in previously filled areas post COVID-19 vaccination. Results From January 2021 to July 2021, we analyzed 20 AE reactions triggered by COVID-19 vaccines in the previously mentioned cohort. They were vaccinated with Pfizer/Biontech (11; 55%), Moderna (5; 25%), Astra-Zeneca (3; 15%), and Sputnik (1; 5%). The most common manifestations were oedema/swelling, angioedema, erythema, skin induration, and granuloma. Less common reactions included myalgia and lymphadenopathy. In 13/20 (65%) cases, the AE appeared after the first dose of vaccine. These inflammatory AE appeared more rapidly after the second dose than after the first one. In 13/20 (65%) cases, the symptomatology subsided with anti-inflammatory/antihistaminic drugs, while spontaneously in 3/20 (15%). The manifestations are ongoing.in the remaining four cases (20%). Conclusion Although probably rare, both RNA-based and adenovirus-based anti-COVID-19 vaccines can cause inflammatory bouts in patients previously treated with DF. In these cases, caution should be paid on subsequent vaccine doses, considering a tailored risk/benefit for any case before next vaccination.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje